GlassScriptPhysician profile
Kristy D Edwards
NPI 1881642080
$2,460.97
in general payments reported to CMS, 2019-2025
26 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $395 · 2021: $459 · 2022: $213 · 2023: $230 · 2024: $444 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $570.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $337.23 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $217.55 | 2021-2024 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.59 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $208.25 | 2020-2025 | Jardiance, Mounjaro |
| Abbott Laboratories | $135.19 | 2023-2025 | Ultreon, Octrode |
| Amgen INC. | $102.01 | 2023-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $69.79 | 2019-2025 | Shingrix |
| Allergan, INC. | $69.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $67.14 | 2022-2023 | |
| Pfizer INC. | $64.09 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $53.99 | 2019-2021 | |
| Exact Sciences Corporation | $48.41 | 2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $40.80 | 2025 | Heplisav-B |
| Mannkind Corporation | $38.78 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.52 | 2020-2021 | |
| Amarin Pharma, INC. | $28.30 | 2021-2022 | |
| Indivior INC. | $24.73 | 2025 | Sublocade |
| Astellas Pharma US INC | $24.44 | 2024 | Veozah |
| Seqirus USA INC | $19.33 | 2025 | Fluad, Flucelvax |
| Supernus Pharmaceuticals, INC. | $19.04 | 2024 | Qelbree |
| Eisai INC. | $18.90 | 2021 | |
| Genentech USA, INC. | $17.71 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.14 | 2020 | |
| Pharmacosmos Therapeutics INC. | $14.78 | 2025 | Monoferric |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristy Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.